The approved indication involves using durvalumab in combination with chemotherapy as a neoadjuvant treatment, followed by durvalumab monotherapy post-surgery. Shares of Astrazeneca Pharma India Ltd ended at ₹6,749, down by ₹113.25, or 1.65%, on the BSE.
